OlatoyosiMOdenikeMD

PubMed

• 995 citations
  International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
  Daniel A Arber, Attilio Orazi, Robert P Hasserjian, Michael J Borowitz, Katherine R Calvo
  Blood. 2022-09-15
• 36 citations
  Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
  Hagop M. Kantarjian, S. Padmanabhan, Wendy Stock, Martin S. Tallman, Gregory A. Curt
  Investigational New Drugs. 2012-06-01
• 258 citations
  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatm...
  Ayalew Tefferi, Giovanni Barosi, Ruben A. Mesa, Francisco Cervantes, H. Joachim Deeg
  Blood. 2006-09-01

Journal Articles

• How I Treat Blast Phase of Philadelphia-Negative Myeloproliferative Neoplasms  
  Olatoyosi Odenike, MD, Blood
• T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia  
  Alachkar H, Mutonga M, Malnassy G, Park JH, Fulton N, Woods A, Meng L, Kline J, Raca G, Odenike O, Takamatsu N, Miyamoto T, Matsuo Y, Stock W, Nakamura Y, Oncotarget, 1/1/2015
• Telomerase Imetestat for patients with essential thrombocythemia  
  Baerlocher G., Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Roth A, ,Daskalakis M, Burington B, Stuart M, Snyder DS, N Engl J Med, 1/1/2015
• Vosaroxin plus cytarabine versus placebo plus cytarabine nin patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomized, controlled, doub...  
  Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig A, Vey N, Strickland SA, Schiller GJ, , Jabbour E, Erba HP, Pigneux A, Horst A, Recher, C, Klimek, VM, Cortes, J, Feld..., Lancet Oncol, 1/1/2015
• Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies  
  Tallarico M, Odenike O, Curr Hematol Malig Rep, 1/1/2015
• Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including ...  
  Odenike O, Onida F, Padron E, Am Soc Clin Oncol Educ Book, 1/1/2015
• Clinical Cancer Advances 2015: annual report on progress against cancer from the American Society of clinical oncology  
  Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O’Day SJ, Odenike O, Ryan CJ, Schilsky RL, Sc..., J Clin Oncol, 1/1/2015
• Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?  
  Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, Fauble V, Finazzi G, Pane F, Mascarenhas J, Prchal J, Giralt S, Hoffman R, Bone Marrow Transplant, 1/1/2015
• A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies  
  Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock, W, Investigational New Drugs, 1/1/2015
• Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myeloid Leukemia (AML): A University of Chicago Phase II Consortium Trial  
  Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison TG, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L..., Clin Cancer Res, 1/15/2014
• Treatment of myeloproliferative neoplasms  
  Yacoub A, Odenike O, Verstovsek S, Current Hem Malig Report, 1/1/2014
• Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients  
  Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike O, Larson RA, van Besien K, Artz S, Hematologica, 1/1/2014
• Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable remissions with imatinib  
  Cheah CY, Burbury K, Apperly JF, Huguet F, Pitini V, Gardembas M, Ross DM, Forrest D, Genet P, Rousselot P, Patton N, Smith G, Dunbar CE, Ito S, Aguiar RC, Odenike O, ..., Blood, 1/1/2014
• Interim analysis of the safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts  
  Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O’Neil..., J. Hematol Oncol, 1/29/2013
• Beyond JAK inhibitor therapy in Myelofibrosis  
  Odenike O, Hematology, 1/1/2013
• A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high risk myelodysplastic syndromes  
  Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W, Bone Marrow Transplant, 1/1/2013
• Immune Reconstitution after Combined Haploidentical and Umbilical Cord Blood Transplantation  
  Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, Savage PA, W..., Leuk Lymphoma, 1/22/2012
• A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia  
  Hossain, Jain N, McConville J, Anastasi J and Odenike O, Chest, 1/1/2012
• Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th...  
  Abel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian J..., Am J Hematol, 1/1/2012
• Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia  
  Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O’Brien S, Leuk Lymphoma, 1/1/2012
• Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia  
  Jamieson K, Odenike O, Expert Opin Pharmacother, 1/1/2012
• Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia  
  Kantarjian H, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, A..., Invest New Drugs, 1/15/2011
• Allogeneic stem cell transplantation in renal failure Engraftment and Prolonged Survival, but High Incidence of Neurologic Toxicity  
  van Besien K, Schouten V, Parsad S, Smith S, Odenike O, Artz A, Leuk Lymphoma, 1/13/2011
• Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation  
  van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Cerro PD, Larson RA, Artz AS, Biol Blood Marrow Transplant, 1/9/2011
• The Dawn of the Molecular Era of the Myelodysplastic syndromes  
  Odenike O and LeBeau MM, New England Journal of Medicine, 1/1/2011
• Join now to see all

Books/Book Chapters

• Treatment strategies-Hematology 
  Chapter: Targeted therapeutic approaches for myelofibrosis 
  Curran E and Odenike O2014
• Oncology – An Evidence-Based Approach 
  Chapter: Acute Lymphoblastic Leukemia 
  Page 1173 - 2000Odenike OM, Michaelis L, Stock WEditors: Chang AE, Ganz PA, Hayes DF, Kinsella T, Pass HI, Schiller JH, Stone R, Stretcher.Edition 1st,2006
• Griffith’s 5-minute Clinical Consult 
  Chapter: Myeloproliferative diseases 
  Page 736 - 737Odenike OMEditors: Mark R. Dambro.Edition 13th,2005
• Oncologic Therapies 
  Chapter: Chronic lymphocytic leukemia 
  Page 231 - 242Odenike OM, Larson RAEditors: E.E. Vokes and HM Golomb.Edition 2nd,2003
• Cancer Medicine 
  Chapter: Recurring chromosome rearrangements in human cancer 
  Page 88 - 107Olopade OI, Sobulo OM, Rowley JDEditors: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, and Frei E.Edition 5th,2000
• Contemporary Management of Myeloproliferative Neoplasms 
  Chapter: Myelofibrosis: Risk stratification and therapeutic strategies 
  Jasielec J and Odenike OEditors: Stein BL and McMahon B.
• Join now to see all

Abstracts/Posters

• Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Biomarker Modulation By Mivebresib (ABBV-075) +/_ Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors
  Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long term Results in Myeloproliferative Neoplasms and Myelodysplastic Syndromes
  Odenike OM, ASCO poster discussion session- Leukemia, Myelodysplasia and Transplantation track, 1/1/2016
• CML and Ph- Myeloproliferative Diseases
  Odenike OM, ASCO Annual Meeting, Chicago, IL, 1/1/2011
• Join now to see all

Lectures

• Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute ... 
  2019 ASCO Annual Meeting - 6/1/2019
• A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Rela... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clonal Hematopoiesis and how it can confound the results of germline and somatic mutation testing 
  1/1/2016
• Targeted therapies in Myelofibrosis 
  Boston University, Boston, MA - 1/1/2016
• Imetelstat, what is the best setting? 
  Dallas, TX - 1/1/2016
• Myelofibrosis: Pathogenesis, Novel therapeutic approaches 
  Philadelphia, PA - 1/1/2015
• Frontline Therapies in Myelodysplastic Syndrome 
  Chicago, IL - 1/1/2015
• MDS Intergroup Trial 
  Multiple locations, 2011 2012, 2014, 2015 - 1/1/2015
• Update on targeted therapies in acute and chronic leukemias 
  Lombard, IL - 1/1/2015
• Leukemia Track/Myelodysplasia track 
  Chicago, IL - 1/1/2015
• S Focus on Myeloproliferative Neoplasm & Myelodysplastic Syndrome 
  Alexandria, VA - 1/1/2015
• Novel Therapies in Myelofibrosis 
  San Diego, CA - 1/1/2015
• Myelodysplastic Syndromes, Concept in Development 
  Chicago, IL - 1/1/2015
• Myelodysplastic Syndromes- Molecular Pathogenesis and novel treatment options 
  Tzaizhou Province, China - 1/1/2015
• Therapeutic Targeting of Epigenetic changes in myeloid neoplasms 
  Chicago, IL - 1/1/2014
• Myeloproliferative Neoplasms 
  Atlanta, GA, 2014; Seattle, WA, 2014 - 1/1/2014
• Beyond JAK inhibitors in Myelofibrosis 
  Mexico City, Mexico - 1/1/2014
• US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes 
  Dana Point, CA - 1/1/2014
• Myelodysplastic Syndromes “Where do we go from here?” 
  Chicago, IL - 1/1/2014
• Epigenetic Therapy in MPNs 
  San Francisco, CA - 1/1/2014
• RAS as a therapeutic target in AML 
  Chicago, IL - 1/1/2014
• Epigenetic modulators in the peritransplantation period 
  New Orleans, LA - 1/1/2013
• MDS Intergroup trial update 
  Chicago, IL - 1/1/2013
• Myelofibrosis, Research to Practice 
  1/1/2013
• Beyond ruxolitinib therapy in Myelofibrosis 
  1/1/2013
• Join now to see all

Other

• ”Ibrutinib will change the CLL landscape” Expert opinion on CLL Resonate Ibrutinib study 
  Oncology times
  1/1/2014
• It takes more than a JAK-hammer to crack the case 
  ASH News Daily
  1/1/2013
• Nature Reviews Drug Discovery 10: 717-18, Companies hope for kinase inhibitor JAKpot 
  News and Analysis
  1/1/2011
• Early Clinical Finding with JAK2 Inhibition in Myelofibrosis 
  The ASCO Post
  1/1/2011
• Expert opinion on chemotherapy+imatinib in Ph+ acute lymphoblastic leukemia (Interview) 
  The ASCO Post
  1/1/2010
• Novel therapeutic approaches for Myelofibrosis with Myeloid Metaplasia 
  Odenike OM, ASCO Educational Book
  www.asco.org
  1/1/2007
• Join now to see all